CrossBridge Bio Secures Funding to Advance Targeted Cancer Therapies

CrossBridge Bio, a biotech company developing dual-payload antibody-drug conjugates (ADCs) for targeted cancer therapies, has closed a seed financing round led by TMC Venture Fund and CE-Ventures, with support from other investors. 

Based on groundbreaking research by Dr. Kyoji Tsuchikama and Dr. Zhiqiang An from UTHealth Houston, CrossBridge Bio's platform combines novel and established antibodies with various payload mechanisms to create ADCs with unique properties and safety profiles. The funding will advance its lead program, CBB-120, a potential best-in-class TROP-2 dual-payload ADC for solid tumors, and support further development of its proprietary linker technology to enhance drug safety and efficacy.

Learn more